Atrovent HFA (Ipratropium Bromide Inhalation) - Summary

ATROVENT HFA SUMMARY

The active ingredient in ATROVENT HFA Inhalation Aerosol is ipratropium bromide.

ATROVENT HFA Inhalation Aerosol is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema.

ATROVENT HFA NEWS HIGHLIGHTS

Published Studies Related to Atrovent HFA (Ipratropium Cation Inhalation)

Ipratropium bromide HFA. [2005]

more>>

Clinical Trials Related to Atrovent HFA (Ipratropium Cation Inhalation)

Acute Bronchodilator Response of a Single Dose of Atrovent or Berotec on Top of Pharmacodynamic Steady State of Spiriva [Completed]

Effect of Ipratropium on Acute Bronchitis in Subjects Without Underlying Lung Disease [Completed]

Tiotropium Inhalation Capsules and Atrovent MDI Comparison Trial in Taiwan [Completed]

A Comparison of Levalbuterol Plus Ipratropium With Levalbuterol Alone in the Treatment of Acute Asthma Exacerbation [Recruiting]

A Comparison of 18g of Tiotropium Inhalation Capsules Once Daily and Atrovent Metered Dose Inhaler (2 Puffs of 20g, 4 Times Daily) in a Double-Blind, Double-Dummy, Efficacy and Safety Study in Adults With Chronic Obstructive Pulmonary Disease (COPD) [Completed]

more>>